About: Jessica Cusato

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Jessica Cusato Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) researcher (en) 연구원 (ko) 研究者 (ja) araştırmacı (tr) wetenschapper (nl) дослідниця (uk) वैज्ञानिक (hi) 研究者 (zh) հետազոտող (hy) hulumtuese (sq)
rdfs:label	Jessica Cusato (en) Jessica Cusato (es) Jessica Cusato (it) Jessica Cusato (nl) Jessica Cusato (ast)
skos:prefLabel	Jessica Cusato (en) Jessica Cusato (es) Jessica Cusato (it) Jessica Cusato (nl) Jessica Cusato (ast)
name	Jessica Cusato (en) Jessica Cusato (es) Jessica Cusato (it) Jessica Cusato (nl) Jessica Cusato (ast)
Scopus author ID	wds:Q57063338-3BBD242F-1D54-4425-A069-241020EBD4D9
Scopus author ID	37112059200
given name	wds:Q57063338-C1E9BD01-367D-4E4C-91D5-5ACEF1F13EC0
given name	Jessica
instance of	wds:Q57063338-463A42D8-6833-426A-B467-8096CFEC3249
instance of	Homo sapiens
occupation	wds:Q57063338-A1F0AE73-3365-482B-A853-1247A28A6C62
sex or gender	wds:Q57063338-D4E153D5-8BEE-402C-9877-E856986C89F6
on focus list of Wikimedia project	wds:Q57063338-38D76B75-9359-4A3C-B9F4-7510CEF38F9B
occupation	researcher
sex or gender	female organism
on focus list of Wikimedia project	WikiProject COVID-19
ORCID iD	wds:Q57063338-40A6646D-E6C0-4ACC-AEBE-3DDC619E42D9
ORCID iD	https://orcid.org/0000-0003-1977-9694
ORCID iD	0000-0003-1977-9694
Iris-AperTO author ID	wds:Q57063338-18D244DD-56EF-4F19-8291-972DD98E3F9C
Iris-AperTO author ID	32206
ResearcherID	wds:Q57063338-E591CB70-CA47-465E-86CB-77CD9C07403C
ResearcherID	K-8927-2016
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57063338
is author of	Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D. Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring? Efavirenz pharmacogenetics in a cohort of Italian patients. A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy Vitamin D pathway gene variants and HCV-2/3 therapy outcomes Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children Pharmacogenetics of ribavirin-induced anemia in HCV patients Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection. Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B. Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia. Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. Cannabinoids concentration variability in cannabis olive oil galenic preparations. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC) High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients Clinical relevance of deferasirox trough levels in β-thalassemia patients. UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients. Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics Role of pharmacogenetics on deferasirox AUC and efficacy. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment Prophylactic Drug Monitoring of Itraconazole in an Oncohematological Pediatric Patient Population

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software